Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7666 to 7680 of 7964 results

  1. Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]

    Discontinued [GID-TAG496]

    Technology appraisal guidance
    Discontinued

  2. Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Evidence summary
    Published
    25 November 2014

  3. Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]

    In development [GID-TA10747] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Everolimus for the treatment of prophylaxis of organ rejection in cardiac transplantation [ID114]

    Discontinued [GID-TAG232]

    Technology appraisal guidance
    Discontinued

  5. Kidney transplantation (rejection) - everolimus [ID117]

    Discontinued [GID-TAG241]

    Technology appraisal guidance
    Discontinued

  6. Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]

    In development [GID-TA11697] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Intravaginal sling for stress urinary incontinence

    Discontinued [GID-IP267]

    Interventional procedures guidance
    Discontinued

  8. Cystic fibrosis: long-term azithromycin (ESUOM37)

    This evidence summary has been updated and replaced by NICE guideline NG78.

    Evidence summary
    Published
    25 November 2014

  9. Systemic lupus erythematosus: oral mycophenolate (ESUOM36)

    This evidence summary has been withdrawn following the MHRA pregnancy-prevention advice issued for women and men taking mycophenolate.

    Evidence summary
    Published
    18 November 2014

  10. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development [GID-TA11546] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Danis stent for acute oesophageal variceal bleeds (MIB185)

    This advice has been updated and replaced by NICE medical technologies guidance 57.

    Medtech innovation briefing
    Published
    17 June 2019

  12. SEM Scanner for pressure ulcer prevention (MIB182)

    This advice has been updated and replaced by NICE medical technologies guidance 51.

    Medtech innovation briefing
    Published
    8 May 2019

  13. LiverMultiScan for liver disease (MIB181)

    This medtech innovation briefing has been updated and replaced by NICE diagnostics guidance on MRI-based technologies for assessing non-alcoholic fatty liver disease (DG50).

    Medtech innovation briefing
    Published
    26 April 2019

  14. Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

    Discontinued [GID-TA10591]

    Technology appraisal guidance
    Discontinued

  15. Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]

    Discontinued [GID-TA10574]

    Technology appraisal guidance
    Discontinued